Celiac Disease Presenting as Hepatic Manifestation (Celiac Hepatitis)

Diagnosis and Screening

• In adults without alcohol use or metabolic syndrome who present with newly diagnosed chronic liver disease and a positive IgA anti‑tissue transglutaminase (IgA‑TTG) test, celiac disease with associated liver injury (“celiac hepatitis”) is the most likely diagnosis. European Society of Hematology (2024) and American Association for the Study of Liver Diseases (AASLD, 2020) recommend screening for celiac disease in any patient with unexplained chronic liver enzyme elevation. [1][2]3

• Celiac disease should be strongly suspected when unexplained chronic liver disease co‑exists with positive IgA‑TTG, especially in the absence of traditional metabolic risk factors. Both the 2024 European guidelines and the 2020 AASLD guidelines endorse this approach. [1][2]

Epidemiology

• Celiac disease is identified in 1.5 %–9 % of patients who have elevated transaminases of unknown origin. Gastroenterology (2006). 3

Hepatic Manifestations of Celiac Disease

• Patients with celiac disease have an increased risk of metabolic‑dysfunction‑associated steatotic liver disease (MASLD) and fatty liver even when they lack classic metabolic‑syndrome features. Nature Reviews Gastroenterology & Hepatology (2024). 4

• Ongoing liver injury in celiac disease can be monitored by elevated serum transaminases during follow‑up. Nature Reviews Gastroenterology & Hepatology (2024). 4

Differential Diagnosis – Autoimmune Hepatitis (AIH)

• AIH diagnosis requires elevated IgG (typically >1.3 × upper limit of normal), presence of autoantibodies (ANA, SMA, anti‑LKM1, anti‑SLA), and compatible liver histology. European Association for the Study of the Liver (EASL, 2025). [5][6]

• AIH usually presents with IgG elevation, not isolated IgA‑TTG positivity. EASL (2025). 5

Confirmatory Testing for Celiac Hepatitis

• Serology: Confirm IgA‑TTG positivity with IgA anti‑endomysial antibodies (EMA) and verify total serum IgA to exclude IgA deficiency. AASLD (2020). 2

• Duodenal biopsy: Histological confirmation (villous atrophy, crypt hyperplasia, increased intra‑epithelial lymphocytes) is essential. EASL (2025) and AASLD (2020). [5][2]

• Biopsy protocol: Obtain ≥ 4 duodenal samples from the second/third portion of the duodenum during upper endoscopy. AASLD (2020). 2

• Liver biopsy: Consider when the diagnosis remains uncertain or when co‑existing liver disease is suspected. European Society of Hematology (2024) and Journal of Hepatology (2018). [1][7]

Exclusion of Other Chronic Liver Diseases

Treatment Response

• A strict gluten‑free diet leads to normalization of liver enzyme abnormalities in the majority of patients (typically within one year). Nature Reviews Gastroenterology & Hepatology (2024). 4

Common Pitfalls

• Do not rely solely on a positive IgA‑TTG in chronic liver disease – confirm with EMA and biopsy because false‑positive rates are high in this setting. (Guideline recommendation implied; specific citation excluded as “ignore ref”.)

• Normal transaminases do not exclude significant hepatic involvement in celiac disease. Nature Reviews Gastroenterology & Hepatology (2024). 4

• Do not confuse celiac disease with AIH; AIH is characterized by elevated IgG and a distinct autoantibody profile, not isolated IgA‑TTG positivity. EASL (2025). [5][6]

• Assay variability: Use human recombinant TTG assays to reduce false‑positive results in liver disease patients. (Guideline recommendation implied; specific citation excluded as “ignore ref”.)

Celiac Disease and Elevated Liver Enzymes: Evidence‑Based Guidelines

Prevalence and Screening

• Approximately 18–25 % of newly diagnosed celiac patients have elevated ALT or AST, and more than 80 % of these enzyme abnormalities normalize within 3–12 months of strict gluten‑free diet adherence【8】【9】.
• In individuals evaluated for unexplained elevated transaminases, the prevalence of underlying celiac disease ranges from 1.5 % to 9.0 %, supporting routine consideration of celiac testing in this context【8】【9】【10】【11】.

Guideline Recommendations for Testing

• The American Gastroenterological Association advises maintaining a low threshold for celiac serology in patients with cryptogenic transaminase elevation, emphasizing screening as a key clinical scenario【8】【12】.
• At the time of celiac disease diagnosis, clinicians should routinely obtain baseline liver enzymes (AST, ALT, alkaline phosphatase) to identify concurrent hepatic involvement【13】.
• The British Society of Gastroenterology (2014) recommends annual liver enzyme assessment in patients with established celiac disease to monitor dietary adherence and detect associated autoimmune conditions【13】.

Response to Gluten‑Free Diet

• The ESPEN guideline (2020) specifically recommends a gluten‑free diet for celiac patients with elevated liver enzymes, reporting transaminase normalization rates of 75 %–100 % after dietary intervention【14】【15】【16】.

Management Algorithm

• If liver enzymes are elevated at celiac diagnosis, initiate a strict gluten‑free diet and re‑measure enzymes at 3, 6, and 12 months; extensive hepatic work‑up is deferred unless enzymes remain abnormal after one year of documented dietary adherence.

Coexisting Autoimmune Hepatitis

• When celiac disease co‑exists with autoimmune hepatitis (prevalence ≈ 2.9 %–6.4 %), simultaneous treatment of both conditions is required to achieve normalization of liver enzymes【8】【9】.

Diagnostic Pitfalls

• Advanced liver disease can produce false‑positive tissue transglutaminase (TTG) IgA antibodies, particularly when older guinea‑pig–derived assay kits are used, potentially leading to misdiagnosis【8】【9】【10】【11】.

Risk of NAFLD/NASH

• Celiac disease is associated with an increased risk of non‑alcoholic fatty liver disease / non‑alcoholic steatohepatitis, with a pooled hazard ratio of 2.8 in adults and 4.6 in pediatric populations, indicating that some patients may develop dual pathology despite gluten‑free diet adherence【14】【15】【16】.